tradingkey.logo

tradingkey.logo
怜玢


Alamar Biosciences Ord Shs

ALMR
りォッチリストに远加
20.590USD
+0.150+0.73%
終倀 06/01, 16:00ET15分遅れの株䟡
1.42B時䟡総額
--盎近12ヶ月PER


詳现情報 Alamar Biosciences Ord Shs 䌁業名

Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.

Alamar Biosciences Ord Shsの䌁業情報


䌁業コヌドALMR
䌚瀟名Alamar Biosciences Inc
䞊堎日Apr 17, 2026
最高経営責任者「CEO」Luo (Yuling)
埓業員数- -
蚌刞皮類Ordinary Share
決算期末- -
本瀟所圚地47071 Bayside Pkwy
郜垂FREMONT
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号94538
電話番号15106269888
りェブサむトhttps://alamarbio.com
䌁業コヌドALMR
䞊堎日Apr 17, 2026
最高経営責任者「CEO」Luo (Yuling)

Alamar Biosciences Ord Shsの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
,
,
--
--
Mr. Yuling Luo, Ph.D.
Mr. Yuling Luo, Ph.D.
Founder, Chairman of the Board, Chief Executive Officer
Founder, Chairman of the Board, Chief Executive Officer
--
--
Mr. Timothy (Tod) White, J.D.
Mr. Timothy (Tod) White, J.D.
President
President
--
--
Mr. Shiping (Steve) Chen, Ph.D.
Mr. Shiping (Steve) Chen, Ph.D.
Founder, Chief Operating Officer, Director
Founder, Chief Operating Officer, Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Justin Mcanear
Mr. Justin Mcanear
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Independent Director
Independent Director
--
--
Dr. Nicholas J. Naclerio, Ph.D.
Dr. Nicholas J. Naclerio, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ian W. Ratcliffe
Mr. Ian W. Ratcliffe
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
,
,
--
--
Mr. Yuling Luo, Ph.D.
Mr. Yuling Luo, Ph.D.
Founder, Chairman of the Board, Chief Executive Officer
Founder, Chairman of the Board, Chief Executive Officer
--
--
Mr. Timothy (Tod) White, J.D.
Mr. Timothy (Tod) White, J.D.
President
President
--
--
Mr. Shiping (Steve) Chen, Ph.D.
Mr. Shiping (Steve) Chen, Ph.D.
Founder, Chief Operating Officer, Director
Founder, Chief Operating Officer, Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Justin Mcanear
Mr. Justin Mcanear
Chief Financial Officer
Chief Financial Officer
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Wed, Apr 22
曎新時刻: Wed, Apr 22
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Qiming Venture Partners
15.29%
Luo (Yuling Ph.D.)
9.68%
Illumina Innovation Funds
9.18%
Sherpa Healthcare Partners
6.92%
Sands Capital Ventures LLC
6.10%
他の
52.83%
株䞻統蚈
株䞻統蚈
比率
Qiming Venture Partners
15.29%
Luo (Yuling Ph.D.)
9.68%
Illumina Innovation Funds
9.18%
Sherpa Healthcare Partners
6.92%
Sands Capital Ventures LLC
6.10%
他の
52.83%
皮類
株䞻統蚈
比率
Individual Investor
17.49%
Venture Capital
15.29%
Corporation
9.18%
Investment Advisor
6.92%
Hedge Fund
6.10%
他の
45.02%

機関投資家保有株


曎新時刻: Tue, Apr 21
曎新時刻: Tue, Apr 21
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q2
3
19.32M
29.05%
+19.32M

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
デヌタなし
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™